Tax Matters - Deferred Taxes (Details) - USD ($) $ in Millions		Dec. 31, 2023	Dec. 31, 2022
Deferred Tax Assets
Prepaid/deferred items - Deferred tax assets	[1],[2]	$ 2,658	$ 1,673
Accrued/deferred royalties - Deferred tax assets	[2]	1,655	2,127
Deferred revenues - Deferred tax assets	[2],[3]	471	95
Inventories - Deferred tax assets	[2],[4]	1,210	672
Intangible assets - Deferred tax assets	[2],[5]	1,526	1,445
Property, plant and equipment - Deferred tax assets	[2]	168	112
Employee benefits - Deferred tax assets	[2],[6]	1,085	1,314
Restructurings and other charges - Deferred tax assets	[2]	537	302
Legal and product liability reserves - Deferred tax assets	[2]	430	385
Research and development - Deferred tax assets	[2],[7]	6,275	4,137
Net operating loss/tax credit carryforwards - Deferred tax assets	[2],[8],[9]	2,708	2,224
State and local tax adjustments - Deferred tax assets	[2]	119	151
Investments - Deferred tax assets	[2],[10]	133	91
All other - Deferred tax assets	[2]	62	78
Subtotal - Deferred tax assets	[2]	19,037	14,806
Valuation allowances	[2]	(1,738)	(1,541)
Total deferred taxes - Deferred tax assets	[2]	17,299	13,265
Deferred Tax Liabilities
Prepaid/deferred items - Deferred tax liabilities	[1],[2]	(654)	(533)
Inventories - Deferred tax liabilities	[2],[4]	(1,060)	(262)
Intangible assets - Deferred tax liabilities	[2],[5]	(11,605)	(6,288)
Property, plant and equipment - Deferred tax liabilities	[2]	(2,039)	(1,845)
Employee benefits - Deferred tax liabilities	[2],[6]	(287)	(276)
Unremitted earnings - Deferred tax liabilities	[2]	(60)	(51)
Investments - Deferred tax liabilities	[2],[10]	(395)	(208)
All other - Deferred tax liabilities	[2]	(72)	(56)
Deferred tax liabilities, gross	[2]	(16,172)	(9,519)
Net deferred tax asset	[2],[11],[12]	$ 1,128	$ 3,746

[1] The increase in net deferred tax assets in 2023 is primarily related to temporary differences associated with the timing of cash tax payments made and accruals recorded in the ordinary course of business.

[2] The deferred tax assets and liabilities associated with global intangible low-taxed income are included in the relevant categories. See Note 1Q.

[3] The increase in deferred tax assets in 2023 is primarily related to temporary differences associated with the non-cash revenue reversal for Paxlovid recorded in the fourth quarter of 2023. See Note 17C.

[4] (c)The decrease in net deferred tax assets in 2023 is primarily due to the acquisition of inventories related to Seagen, partially offset by the temporary differences associated with the non-cash charges for inventory write-offs for Paxlovid and Comirnaty.

[5] The increase in net deferred tax liabilities in 2023 is primarily due to the acquisition of intangible assets related to Seagen, partially offset by the amortization of intangible assets and certain impairment charges.

[6] The decrease in net deferred tax assets in 2023 is primarily due to changes in pension and postretirement benefit obligations, as well as the performance of plan assets reported in the period. See Note 11.

[7] The increase in deferred tax assets in 2023 is primarily related to the acquisition of capitalized R&D costs related to Seagen and the TCJA requirement to capitalize R&D costs for tax years beginning after December 31, 2021.

[8] The amounts in 2023 and 2022 are reduced for unrecognized tax benefits of $1.3 billion and $1.2 billion, respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position.

[9] The increase in deferred tax assets in 2023 is primarily due to the acquisition of net operating loss carryforwards and credit carryforwards related to Seagen. See Note 2A.

[10] The increase in net deferred tax liabilities in 2023 is primarily due to the impact of foreign currency translation adjustments related to our equity-method investment in Haleon/the Consumer Healthcare JV. See Note 2C.

[11] Excludes indefinite- and definite-lived deferred tax assets for certain non-U.S. tax losses and interest carryforwards and U.S. state general business credits, totaling $11.1 billion, given that management has determined based on applicable accounting rules that it is remote that these tax attributes will be utilized.

[12] In 2023, Noncurrent deferred tax assets and other noncurrent tax assets ($1.8 billion), and Noncurrent deferred tax liabilities ($0.6 billion). In 2022, Noncurrent deferred tax assets and other noncurrent tax assets ($4.8 billion), and Noncurrent deferred tax liabilities ($1.0 billion).